3D Printed Coronary Models Closely Matched Invasive FFR in Coronary Ischemia Testing
Functional assessment of coronary stenosis has long rested on invasive pressure wire measurements, yet the push to reduce procedural burden has kept noninvasive approaches in active development. A study in Frontiers in Cardiovascular Medicine tested a patient-specific 3D printing strategy designed to estimate coronary artery ischemia from coronary CT angiography, then compared it directly with invasive fractional flow reserve. The result was a strong correlation between the two methods and a narrow mean bias, suggesting that an in vitro model built from imaging data can reproduce clinically relevant pressure relationships inside diseased coronary arteries.
The method centered on FFR3D, a novel framework that starts with non-invasive coronary CT angiograms and ends with a physically printed model of each patient’s epicardial coronary anatomy. Investigators included 28 patients with varying degrees of coronary artery disease who had undergone both coronary CT angiography and invasive fractional flow reserve assessment. Their coronary arteries were segmented and reconstructed with Mimics software, then printed using a Carbon M1 3D printer and urethane methacrylate rigid resins. The model was not intended as a static anatomic replica alone. It was built to mimic coronary physiology by incorporating flow-dependent stenosis resistance in series with variable downstream resistance, allowing pressure changes to be observed under different flow conditions.
How the In Vitro Coronary System Simulated Physiology
Coronary ischemia is driven not just by the visible narrowing of a vessel but by how that narrowing behaves under changing flow demand. A lesion that appears moderate on imaging may impose a much larger pressure drop when flow rises, especially when downstream resistance and microvascular conditions are factored into the equation. The printed model attempted to approximate that physiology by applying a range of flow rates through a peristaltic steady flow pump and titrating flow with a sensor. Patient-specific aortic pressure and differing flow conditions were then used to calculate the pressure drop and the distal-to-proximal pressure ratio, or Pd/Pa.
This is a notable design choice because invasive FFR itself is fundamentally a pressure-based index. By recreating the coronary geometry and pairing it with controllable flow conditions, the model aimed to translate anatomical information into a functional estimate of lesion severity. In practical terms, it tries to answer the clinical question that imaging alone often cannot settle: does this stenosis actually reduce perfusion enough to matter?
The biological logic is straightforward. Coronary flow limitation is a function of vessel caliber, lesion shape, and resistance along the downstream vascular bed. A model that captures those variables can approximate the same pressure gradients that catheter-based FFR measures in vivo. The study’s focus on pressure ratio rather than anatomy alone places it squarely in the functional testing space, where treatment decisions are often made.
Correlation With Invasive FFR Was Strong and Bias Was Small
The key numerical finding was a correlation coefficient of 0.87 between FFR3D and invasive FFR, with p < 0.0001. In a comparative physiology study, that is a substantial association and suggests the printed model tracked the invasive reference closely across the studied range. Bland-Altman analysis showed a mean bias of 0.02, with limits of agreement from -0.14 to 0.18, and the bias itself was not statistically significant (p = 0.2). In other words, the 3D printed platform did not merely move in the same direction as invasive FFR; it also stayed close to the reference measurement on average.
The divergence that often limits noninvasive tools did not appear severe here. A model can be anatomically impressive and still fail clinically if it does not match the functional consequences of a stenosis. Here, the pressure-derived measurements remained in close agreement with invasive physiology, which is the point at which a promising engineering concept begins to look clinically relevant.
Still, the study remains an early technical validation rather than a practice-changing clinical trial. The cohort was small, and the comparison was made against invasive FFR in a controlled in vitro setup. The results establish feasibility and agreement, but they do not yet define how the platform would perform in larger, more heterogeneous populations or how it might be integrated into real-world decision-making for revascularization.
Where 3D Printed FFR Could Fit in Coronary Care
The appeal of the approach lies in its patient specificity. Coronary disease is heterogeneous, and two patients with similar angiographic narrowing may have very different hemodynamic consequences depending on vessel size, lesion morphology, and flow conditions. A model derived from each person’s own coronary CT angiogram offers a way to test those differences outside the body while preserving individual anatomy. That could be useful when noninvasive imaging leaves uncertainty about whether a lesion is flow-limiting enough to justify intervention.
There is also a workflow advantage in concept, though not yet in proven clinical deployment. Coronary CT angiography is already widely used in selected patients, and 3D printing adds a tangible physical layer to the diagnostic process. If future validation studies confirm reproducibility, turnaround time, and performance across broader lesion types, FFR3D could supplement existing imaging by providing a functional readout without immediate catheterization. For now, the study shows that the bridge between anatomy and physiology can be built with enough fidelity to mirror invasive pressure assessment closely.
One sentence captures the central finding plainly: a patient-specific printed coronary model can reproduce invasive pressure behavior with striking agreement.
That does not settle the larger clinical question of adoption. The study did not address downstream outcomes, cost, reproducibility across centers, or whether the platform improves revascularization decisions compared with current noninvasive pathways. It also did not establish how the system performs in complex coronary anatomy, diffuse disease, or settings where downstream microvascular resistance may alter pressure interpretation. Those are the next hurdles before a 3D printed FFR tool can move from technical validation to everyday use at the bedside.